Navigation Links
Gene Therapy for Hereditary Immunodeficiency Diseases

Since the late 1980s, gene therapy has given rise not only to high expectations of treatment success but also great concerns regarding health risks//. Since the German Research Foundation, Deutsche Forschungsgemeinschaft (DFG) issued its first memorandum in 1995; this field of research has developed enormously.

The second memorandum, which has just been presented by the DFG Senate Commission on Genetic Research, makes it clear that gene therapy already shows signs of success in certain areas, such as severe hereditary immunodeficiency diseases, while in other areas there is still considerable need for research.

Moreover, the clinical application of gene therapy requires careful risk/benefit assessment, although in this respect it does not differ substantially from other therapeutic approaches.

Gene therapy is defined as the introduction of genes into tissues or cells via gene transfer, with the purpose of deriving a therapeutic or preventative benefit from the function of these genes. Gene transfer is achieved using a vector – a kind of vehicle that carries the gene. Somatic gene transfer only targets body cells (somatic cells). Introducing genes into the germline is illegal in Germany.

The first well-documented gene therapy studies were launched in the early 1990s. By 2005 it was estimated that more than 1,100 gene therapy studies had been conducted worldwide, one-third of them in Europe, and a significant number in Germany. The DFG is currently funding a Priority Programme for research groups, some of which are international leaders in their field, that examine the entry and persistence of gene therapy vectors in target cells.

In spite of continued great difficulties with technical implementation, initial successes in somatic gene therapy are on the horizon, for example in treating adenosine deaminase deficiency and chronic granulomatous disease. There are also initial indicators that point to the efficacy of ge ne therapy in treating chronic lymphatic leukaemia and haemophilia B. But successes in clinical testing come with their share of setbacks, such as the currently slight margin of therapeutic effectiveness over unwanted side effects.

This underscores the necessity to carefully assess risks and benefits and also shows that there is still a dire need for more research on gene therapy. Basic research should be conducted in direct collaboration across disciplines, using animal models and clinical studies. An acute need for research exists, especially regarding the development of efficient and safe vectors for gene transfer.

Source-Eurekalert
SRI
'"/>




Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... 2016 , ... To succeed under value-based payments, healthcare providers ... how to move forward, given the need to sustain current operations. PYA has ... an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers want ...
(Date:6/24/2016)... Brooklyn, New York (PRWEB) , ... June 24, 2016 , ... ... medical marijuana patients optimize the ingestion of their medication by matching users with high ... allows users to compare pieces with no commitment. , Inhale was founded by two ...
(Date:6/24/2016)... ... ... Dr. Seema Daulat, a native Texan and University of Texas at Austin ... July 13, 2016. , Dr. Daulat earned her Doctorate of Medicine (MD) at The ... the Agape Clinic serving Dallas’ underprivileged community. , Following medical school, Dr. Daulat completed ...
(Date:6/23/2016)... Los Angeles, CA (PRWEB) , ... June 23, 2016 , ... ... being conducted that may expose a possible link between head and neck cancer in ... individuals participating in the study were evaluated based on whether they had gum disease, ...
(Date:6/23/2016)... ... ... The Mechille Wilson Agency, a Texas-based insurance company that provides coverage to hundreds ... a charity drive to assist a student to be chosen from the local area. ... be presented to the chosen student to help with the growing costs of tuition, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... 2016 Revolutionary technology includes multi-speaker ... , industry leaders in advanced audiology and hearing aid ... Opn ™, the world,s first internet connected hearing aid ... devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) ... of ,world firsts,: , TwinLink™ - the ...
Breaking Medicine Technology: